Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine

Domenico De Berardis, Gabriella Rapini, Luigi Olivieri, Domenico Di Nicola, Carmine Tomasetti, Alessandro Valchera, Michele Fornaro, Fabio Di Fabio, Giampaolo Perna, Marco Di Nicola, Gianluca Serafini, Alessandro Carano, Maurizio Pompili, Federica Vellante, Laura Orsolini, Giovanni Martinotti, Massimo Di Giannantonio

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Pages (from-to)237-256
Number of pages20
JournalTherapeutic Advances in Drug Safety
Volume9
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • adverse effects
  • clozapine
  • life threatening
  • management
  • resistant schizophrenia
  • NEUROLEPTIC MALIGNANT SYNDROME
  • INDUCED GASTROINTESTINAL HYPOMOTILITY
  • TREATMENT-RESISTANT SCHIZOPHRENIA
  • COLONY-STIMULATING FACTOR
  • INDUCED WEIGHT-GAIN
  • TORSADE-DE-POINTES
  • INDUCED AGRANULOCYTOSIS
  • 2ND-GENERATION ANTIPSYCHOTICS
  • INDUCED MYOCARDITIS
  • IN-VITRO

Cite this

De Berardis, D., Rapini, G., Olivieri, L., Di Nicola, D., Tomasetti, C., Valchera, A., Fornaro, M., Di Fabio, F., Perna, G., Di Nicola, M., Serafini, G., Carano, A., Pompili, M., Vellante, F., Orsolini, L., Martinotti, G., & Di Giannantonio, M. (2018). Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. Therapeutic Advances in Drug Safety, 9(5), 237-256. https://doi.org/10.1177/2042098618756261